• 18-80 years old, male and female.

• Subjects voluntarily enrolled in this study and signed the informed consent, good compliance and co-operated with the follow-up.

• Primary hepatocellular carcinoma with postoperative histopathological diagnosis of HCC and negative margins.

• Presence of any of the following high-risk factors for recurrence: ① tumor size ≥5.0cm combined with microvascular invasion; ② number of tumors ≥3; ③ presence of portal vein cancer thrombus (vp1 or vp2 type).

• No recurrence of metastasis confirmed by imaging examination 3-7 weeks after surgery.

• ECOG score of 0-1.

• Expected survival ≥ 3 months.

• Child-Pugh score ≤ 7.

• Subjects with no previous antitumour therapy (except antiviral therapy)

• No extra-hepatic metastases or lymph node metastases.

• No significant abnormality in routine laboratory tests (blood test, liver and kidney function, coagulation function, etc.): (1) Criteria for routine blood tests need to be met (no blood and blood products transfusion within 14 days): a. Absolute neutrophil value (ANC) ≥ 1.5\*10\^9/L; b. Haemoglobin (HGB) ≥ 90g/L; c. Platelet count (PLT) ≥ 75\*10\^9/L. (2) Biochemical tests need to meet the following criteria: a. Serum albumin (ALB) ≥ 35g/L; b. Serum total bilirubin (TBIL) \< 1.5\*Upper Limit of Normal (ULN); c. Serum glutamic transaminase (AST), alanine aminotransferase (ALT) \< 2.5\*ULN; d. Serum creatinine ≤ 1.5\*ULN.